
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Our knowledge of the genetic causes of deafness is advancing rapidly, raising hopes for better diagnosis and more effective treatment in the near future.






